There is a large amount of literature data that shows the effectiveness of cell therapy using mesenchymal stromal cells (MSCs), as on preclinical models and in some clinical studies in small groups of patients.Currently the use of MSC in clinical practice is limited by security considerations. Potential risks associated with their proliferative capacity, the risk of infectious complications, as well as the possible immunogenicity of the cells themselves.Foreign researchers analyzed on the basis of a literature review, the results of which evaluated the clinical safety of MSCs. The article presents the results of our monitoring of patients with inflammatory bowel disease (IBD), which received MSCs in the Department of pathology bowel. The results of our study, and the results, given in the review, should provide scientists and policy-makers the confidence that according to available scientific data an innovative method of cell therapy is safe for clinical use.


  1. Friedenstein A.J., Piatetzky S., Petrakova K.V. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966; 16: 381-90.
  2. Francois S., Bensidhoum M., Mouiseddine M., Mazurier C., et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells, 2006; 24(4):1020-29.
  3. Matthay MA, Goolaerts A, Howard JP, Lee JW. Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med 2010, 38: S569-73.
  4. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007, 4: e269.
  5. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010;182: 1047-57.
  6. Boyle AJ, McNiece IK, Hare JM. Mesenchymal stem cell therapy for cardiac repair. Methods Mol Biol 2010; 660: 65-84.
  7. Князев О.В., Парфенов А.И., Щербаков П.Л., Хомерики С.Г., Ручкина И.Н., Конопляников А.Г. Эффективность и безопасность мезенхимальных стромальных клеток костного мозга у больных с рефрактерными формами болезни Крона. Клеточная трансплантология и тканевая инженерия. 2013. Том VIII, №1, стр. 76-84.
  8. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010; 12: 576-8.
  9. M.M. Lalu, L. McIntyre, C. Pugliese, D.Fergusson, B.W. Winston, et al. Safety of cell therapy with mesenchymal stromal cells (safe cell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012; 7(10): e47559.
  10. Chen S, Liu Z, Tian N, Zhang J, Yei F, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006; 18: 552-56.
  11. Chen SL, Fang WW, Qian J, Ye F, Liu YH, et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 2004; 117: 1443-48.
  12. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54: 2277-86.
  13. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, et al. A long-term follow-up study of intravenous auto-logous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010; 28: 1099-1106.
  14. Lee PH, Kim JW, Bang OY, et al. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2010; 83: 723-30.
  15. Ning H, Yang F, Jiang M, Hu L, Feng K, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008; 22: 593-9.
  16. Wang JA, Xie XJ, He H, Sun Y, Jiang J, et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34: 107-110.
  17. Xie ZW, Cui GX, Li YZ, Li BW, Zhu SW, et al. Curative effect of autologous mesenchymal stem cell transplantation on spinal cord injury. Journal of Clinical Rehabilitative Tissue Engineering Research 2007; 11: 1277-1279.
  18. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010; 16: 838-47.
  19. Gonzalo-Daganzo R, Regidor C, Martin- Donaire T, Rico MA, Bautista G, et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 2009; 11: 278-288.
  20. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 804-811.
  21. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2008; 30: 215-222.
  22. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-564.
  23. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-98.
  24. Liu L, Sun Z, Chen B, Han Q, Liao L, et al. Ex vivo expansion and in vivo infusion of bone marrow-derived Flk-1+CD31-CD34-mesenchymal stem cells: feasibility and safety from monkey to human. Stem Cells Dev 2006; 15: 349-57.
  25. Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimoghaddam K, Sanatkar M, Gasemi M, et al. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med 2007; 10: 467-73.
  26. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-97.
  27. Vanikar AV, Trivedi HL, Feroze A, Kanodia KV, Dave SD, et al. Effect of co-transplantation of mesenchymal stem cells and hematopoietic stem cells as compared to hematopoietic stem cell transplantation alone in renal transplantation to achieve donor hyporesponsiveness. Int Urol Nephrol 2011; 43: 225-32.
  28. Arima N, Nakamura F, Fukunaga A, Hirata H, Machida H, et al. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. Cytotherapy 2010; 12: 265-68.
  29. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, et al. Autologous bone marrow- derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59: 1662-69.
  30. Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007; 39: 3358-62.
  31. Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011; 134: 1790-1807.
  32. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010; 67: 1187-94.
  33. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-86.
  34. Liang J, Zhang H, Hua B, Wang H, Lu L, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010; 69: 1423-29.
  35. Liang J, Zhang H, Wang D, Feng X, Wang H, Hua B, Liu B, Sun L: Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut 2012; 61:468-69.
  36. Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev 2009; 18: 1247-52.
  37. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 2007; 10: 459-66.
  38. Ringden O, Uzunel M, Sundberg B, Lonnies L, Nava S, et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007; 21: 2271-76.
  39. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421-32.
  40. Sun L, Wang D, Liang J, Zhang H, Feng X, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2467-75.
  41. Wang D, Zhang H, Cao M, Tang Y, Liang J, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis 2011; 70: 1285-88.
  42. Weng JY, Du X, Geng SX, Peng YW, Wang Z, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010, 45: 1732-40.
  43. Yang Z, Zhang F, Ma W, Chen B, Zhou F, et al. A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery. Cardiovasc Ther 2010; 28: 380-85.
  44. Zhang X, Li JY, Cao K, Lu H, Hong M, et al. Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases. Int J Lab Hematol 2010; 32: 256-64.
  45. Zhang ZX, Guan LX, Zhang K, Zhang Q, Dai LJ. A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy 2008; 10: 134-39.
  46. Цыб А.Ф., Коноплянников А.Г., Колесникова А.И., Павлов В.В. Получение и использование в медицине клеточных культур из мезенхимальных стволовых клеток костного мозга человека. Вестник Российской Академии медицинских наук 2004; 59(9): 71-76.
  47. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 2009; 108: 759-69.
  48. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-44.
  49. Uccelli A, Moretta L, Pistoia V Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736.
  50. Karlsson H., Samarasinghe S., Ball L.M., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood, 2008; 112, 532-41.
  51. Kang, H.S., Habib, M., Chan, J., Abavana, C., Potian, J.A., Ponzio, N.M., Rameshwar, P. A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. Exp. Hematol., 2005; 33, 796-803.
  52. Rasmusson, I.; Le Blanc, K.; Sundberg, B.; Ringden, O. Mesenchymal stem cells stimulate anti-body secretion in human B cells. Scand J Immunol. 2007; 65, 336-43.
  53. Gazzinelli, R.T., Ropert, C., Campos, M.A. Role of the Toll-interleukin-1 receptor signaling pathway in host resistance and pathogenesis during infection with protozoan parasites. Immunol Rev. 2004; 201: 9-25.
  54. Liotta, F., et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells, 2008; 26: 279-89.
  55. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthay MA. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010 Dec; 28(12):2229-38.
  56. Mei SH., et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010 Oct 15;182(8):1047-57. Epub 2010 Jun 17.
  57. Majumdar M.K., Keane-Мооrе M., Buyaner D. et al. Characterization and functionality of cells surface molecules on human mesenchymal stem cell. J Biomed Sci. 2003; 10(2):228-41.
  58. Syme R, Bewick M, Stewart D, Porter K, Chadderton T, et al. The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity. Biol Blood Marrow Transplant. 2004, 10: 135-141.
  59. Windrum P, Morris TC, Drake MB, Niederwieser D, Ruutu T. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transplant. 2005; 36: 601-3.

Copyright (c) 2014 Knyazev O.V., Konoplyannikov A.G., Parfenov A.I., Ruchkina I.N., Churikova A.A., Albulova E.A., Bykova S.V., Boldyreva O.N., Fadeeva N.A., Lishinskaya A.A., Bondarenko E.Y., Kagramanova A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 38032 от 11 ноября 2009 года.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies